top stories 

  • Apple supplier Luxshare u...

  • Allahabad University entr...

  • New guidelines address ri...

  • Arlette Grao Files A Poli...

  • Brooklyn Beckham, Fiancee...

  • Early Q2 results better t...

  • Britain coronavirus updat...

  • 3rd phase human trial of ...

  • 3 Arrested For Creating F...

Admin Reporter- POOJA1

Oct 16 2020


Remdesivir, hydroxychloroquine did not cut hospital stay or mortality in Covid-19 patients: WHO

Friday, 16 October 2020

Gilead Sciences Inc’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.

 

 


The antiviral medication, among the first to be used as a treatment for Covid-19, was one of the drugs recently used to treat US President Donald Trump’s coronavirus infection.

 

 

 

The results are from WHO’s “Solidarity” trial, which evaluated the effects of four potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, in 11,266 adult patients across more than 30 countries.

instagram imagesfollow us @ instagram